Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis
Authors
Keywords
-
Journal
BIODRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-04
DOI
10.1007/s40259-023-00628-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures
- (2023) Andres Pichon-Riviere et al. Lancet Global Health
- Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
- (2022) Mingjun Rui et al. JOURNAL OF MEDICAL ECONOMICS
- Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).
- (2022) Si-Yang Maggie Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer
- (2022) Will Paces et al. Scientific Reports
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
- (2022) Gilberto de Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- EP08.01-085 Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
- (2022) S.-Y. Liu et al. Journal of Thoracic Oncology
- Phylogenetic reconciliation
- (2022) Hugo Menet et al. PLoS Computational Biology
- IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer
- (2021) Mari Mino-Kenudson et al. Journal of Thoracic Oncology
- Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
- (2021) Wei Xiong et al. Frontiers in Oncology
- Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective
- (2021) Yingcheng Wang et al. Frontiers in Medicine
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2020) Shirish Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
- (2020) Puneet Saxena et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1 ‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE ‐042 China Study
- (2020) Yi‐Long Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
- (2019) Sylvie Lantuejoul et al. Journal of Thoracic Oncology
- PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
- (2018) Enrico Munari et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial
- (2018) Eline M. Krijkamp et al. MEDICAL DECISION MAKING
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health state utilities in patients with advanced non-small-cell lung cancer in China
- (2018) Yunjie Shen et al. Journal of Comparative Effectiveness Research
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
- (2018) Julie R. Brahmer et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
- (2018) Ralph P. Insinga et al. JOURNAL OF MEDICAL ECONOMICS
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Baohui Han et al. JAMA Oncology
- Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States
- (2018) Steven D. Criss et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- New and emerging targeted treatments in advanced non-small-cell lung cancer
- (2016) Fred R Hirsch et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy for lung cancer
- (2016) Antonius Steven et al. RESPIROLOGY
- Immunotherapy for Lung Cancer: No Longer an Abstract Concept
- (2016) Kristen Marrone et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
- (2016) Min Huang et al. JOURNAL OF MEDICAL ECONOMICS
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Modeling Good Research Practices—Overview
- (2012) J. Jaime Caro et al. MEDICAL DECISION MAKING
- Conceptualizing a Model
- (2012) Mark Roberts et al. MEDICAL DECISION MAKING
- Dynamic Microsimulation Models for Health Outcomes
- (2010) Carolyn M. Rutter et al. MEDICAL DECISION MAKING
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started